TABLE 1.
Characteristics of patient cohorts. The clinical parameters of the selected bladder patient cohorts used for CyTOF staining (n = 21), flow staining (n = 20), and TCGA analysis (n = 351) are listed
| Variables | Cohort n = 21 | Cohort n = 20 | Cohort n = 351 |
|---|---|---|---|
| Median age (IQR) | 76 (63.5–80) | 72 (63–81.5) | 69 (60–77) |
| Gender | |||
| Female | 4 (19.05%) | 7 (35%) | 94 (26.8%) |
| Male | 17 (80.95%) | 13 (65%) | 257 (73.2%) |
| Stage | |||
| T0 | 1 (0.28%) | ||
| T1 | 3 (0.85%) | ||
| T2 | 12 (57.14%) | 6 (30%) | 107 (30.48%) |
| T3 | 6 (28.57%) | 8 (40%) | 183 (52.14%) |
| T4 | 3 (14.29%) | 6 (30%) | 57 (16.24%) |
| Histologic subtype | |||
| Pure urothelial carcinoma | 13 (61.90%) | 12 (60%) | |
| Urothelial carcinoma with squamous differentiation | 7 (33.33%) | 4 (20%) | |
| Urothelial carcinoma with small cell carcinoma | 1 (4.76%) | 2 (10%) | |
| Urothelial carcinoma with plasmacytoid differentiation | 1 (5%) | ||
| Urothelial carcinoma with sarcomatoid differentiation | 1 (5%) | ||
| Luminal | 185 (52.71%) | ||
| Nonluminal | 166 (47.29%) | ||
| Prior chemotherapy | |||
| Yes | 8 (38.10%) | 5 (25%) | 62 (17.7%) |
| No | 13 (61.90%) | 15 (75%) | 159 (45.3%) |
| Unknown | 130 (37.0%) | ||
| Prior radiation | |||
| Yes | 3 (14.29%) | 2 (10%) | 230 (65.5%) |
| No | 18 (85.71%) | 18 (90%) | 6 (1.7%) |
| Unknown | 115 (32.8%) | ||